WASHINGTON / RankWire.AI / – A rare inherited genetic mutation has been shown to elevate an individual’s overall likelihood of developing lung cancer by approximately 25 times, with non-smokers facing about a 60-fold increase, according to a study published in the journal Science. The investigation, a collaboration between the Dana-Farber Cancer Institute and the 23andMe Research Institute, analyzed anonymized genomic data from over 3.3 million individuals. The researchers identified the germline variant, known as EGFR T790M, as one of the most potent inherited risk factors for lung cancer discovered to date.
This mutation occurs in the epidermal growth factor receptor gene, which plays a crucial role in regulating cell growth and division within lung tissue. Although somatic EGFR mutations acquired during a person’s lifetime are recognized as drivers of non-small cell lung cancer, the germline T790M variant is inherited from birth and exists in every cell. Data from the National Cancer Institute indicates that this mutation is found in about 1 out of every 15,850 Americans. Lead author Dr. Jaclyn LoPiccolo explained that possessing this variant increases the risk of lung cancer roughly 62 times for never-smokers, compared to approximately 11 times for those with a history of smoking.
Genetic analysis traced the origin of the EGFR T790M mutation to disproportionately affect populations in the Southern Appalachian region, including areas across Tennessee and Alabama. Evolutionary geneticists determined that the mutation originated among British and Irish settlers who migrated to North America during colonial times, with the mutation becoming more prevalent following a genetic bottleneck roughly 200 years ago. Dr. Pasi A. Jänne, senior author of the study, highlighted that while current lung cancer screening primarily focuses on tobacco exposure, recognizing significant genetic risk factors could lead to targeted low-dose computed tomography screening for non-smoking carriers.
Dana-Farber Research Analyzes Over 3.3 Million Genomes
Supported by the National Institutes of Health, preclinical and clinical studies confirmed the strong association between the mutation and lung cancer, showing no significant link to 17 other common cancers examined within the dataset. Oncologists pointed out that although tobacco exposure remains the primary cause of lung cancer, the rise of non-smoking related cases is becoming an increasing concern worldwide. Pharmaceutical companies like AstraZeneca are actively working on developing targeted tyrosine kinase inhibitors such as Tagrisso to treat lung cancers with EGFR mutations when tumors progress.
Co-senior researcher Dr. Alexander Gusev noted that this study illustrates how a single inherited point mutation can have an extraordinarily strong influence on disease risk. Medical professionals advise individuals with multiple family members affected by lung cancer, unexplained lung nodules, or ancestral ties to Southern Appalachia to seek genetic counseling. The researchers emphasized that carrying the mutation does not guarantee a lung cancer diagnosis, as environmental factors and additional genetic changes also play a role in malignant development over a person’s lifetime.
EGFR Gene’s Role in Cellular Growth and Disease Susceptibility
The research team plans to broaden observational efforts through the ongoing INHERIT Study, aiming to assess additional inherited EGFR variants across diverse racial groups. Long-term monitoring will focus on uncovering environmental triggers and secondary genetic alterations that influence why some carriers develop tumors while others remain healthy.
Comprehensive details on population genetics, risk assessments, and screening guidelines are available through peer-reviewed medical repositories and institutional release portals. Future biomarker data will be presented at upcoming international oncology conferences to help shape screening and prevention strategies.